Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (DESTINATION)

NCT03706079 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03706079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03706079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (DESTINATION)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
January 7, 2019
Completion date
May 18, 2022
Enrollment
951 (actual)
Sites
180

Conditions

As the registry lists them; a condition with its own page is linked.

asthma